膀胱癌的三联疗法：现代管理与未来方向。
Trimodality therapy for bladder cancer: modern management and future directions.
机构信息
Department of Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
出版信息
Curr Opin Urol. 2019 May;29(3):210-215. doi: 10.1097/MOU.0000000000000601.
Abstract
PURPOSE OF REVIEW
This review examines both trimodality therapy (TMT) in the definitive management of bladder cancer as well as the use of adjuvant radiotherapy for bladder cancer with a specific focus on publications from the last 2 years.
RECENT FINDINGS
TMT is an effective management strategy for muscle invasive bladder cancer with outcomes similar to radical cystectomy. Effectiveness of this strategy exists in variant histologies and can be personalized with use of biomarkers. There is a role for adjuvant radiotherapy in locally advanced bladder cancer, especially in the age of improved imaging and modern radiotherapy techniques.
SUMMARY
This review should provide the reader data necessary to support use of TMT and adjuvant radiation therapy in their clinic.
摘要
目的综述
本文回顾了膀胱癌的根治性治疗中三联疗法（TMT）以及辅助放疗在膀胱癌中的应用，重点关注了过去 2 年的相关出版物。
最近的发现
TMT 是肌层浸润性膀胱癌的有效治疗策略，其结果与根治性膀胱切除术相似。该策略在不同的组织学类型中均有效，并且可以通过使用生物标志物进行个体化治疗。在局部晚期膀胱癌中，尤其是在影像学技术和现代放疗技术改进的时代，辅助放疗具有一定的作用。
总结
本文应向读者提供支持在临床中使用 TMT 和辅助放疗的必要数据。
相似文献
1
Trimodality therapy for bladder cancer: modern management and future directions.膀胱癌的三联疗法：现代管理与未来方向。
Curr Opin Urol. 2019 May;29(3):210-215. doi: 10.1097/MOU.0000000000000601.
2
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.根治性膀胱切除术联合多模式治疗在肌层浸润性膀胱癌中的保膀胱作用的批判性分析：一项系统性综述。
Eur Urol. 2014 Jul;66(1):120-37. doi: 10.1016/j.eururo.2014.02.038. Epub 2014 Feb 26.
3
Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.肌肉浸润性膀胱癌的三联疗法：最新进展与未解决的问题
Curr Oncol Rep. 2020 Feb 1;22(2):14. doi: 10.1007/s11912-020-0880-5.
4
Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.根治性膀胱切除术与肌肉浸润性膀胱癌的保留器官三联疗法：一项临床试验的系统评价
Crit Rev Oncol Hematol. 2015 Sep;95(3):387-96. doi: 10.1016/j.critrevonc.2015.04.006. Epub 2015 Apr 17.
5
Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.多学科膀胱癌诊疗模式下根治性膀胱切除术与膀胱保留三联疗法的倾向评分分析。
J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327. Epub 2017 Apr 14.
6
Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.当代及新兴的肌层浸润性膀胱癌保膀胱三联疗法。
Hematol Oncol Clin North Am. 2021 Jun;35(3):567-584. doi: 10.1016/j.hoc.2021.02.006. Epub 2021 Apr 15.
7
Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.免疫和基质浸润对肌层浸润性膀胱癌保膀胱三联疗法后结局的影响。
Eur Urol. 2019 Jul;76(1):59-68. doi: 10.1016/j.eururo.2019.01.011. Epub 2019 Feb 1.
8
Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.膀胱癌保留膀胱的三联疗法治疗肌层浸润性膀胱癌。
Curr Oncol Rep. 2018 Jun 30;20(9):66. doi: 10.1007/s11912-018-0711-0.
9
Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.膀胱保留疗法：文献综述及三联疗法的未来方向
Curr Urol Rep. 2018 Nov 3;19(12):108. doi: 10.1007/s11934-018-0859-z.
10
Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.对于淋巴结阴性的局限性肌层浸润性膀胱癌，采用无新辅助化疗的三联保膀胱方法可获得相当的无膀胱切除术生存率。
Radiat Oncol. 2014 Sep 24;9:213. doi: 10.1186/1748-717X-9-213.
引用本文的文献
1
The importance of maximal TURBT in trimodality therapy for muscle-invasive bladder cancer (MIBC).最大程度经尿道膀胱肿瘤切除术在肌层浸润性膀胱癌（MIBC）三联疗法中的重要性。
Bladder Cancer. 2025 Jun 12;11(2):23523735251346569. doi: 10.1177/23523735251346569. eCollection 2025 Apr-Jun.
2
The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond.最大程度经尿道膀胱肿瘤切除术在肌层浸润性膀胱癌中的作用：平衡膀胱保留及其他方面的获益
Cancers (Basel). 2024 Sep 30;16(19):3361. doi: 10.3390/cancers16193361.
3
Mini-Review: Current Bladder Cancer Treatment-The Need for Improvement.综述：当前膀胱癌治疗——亟待改进。
Int J Mol Sci. 2024 Jan 26;25(3):1557. doi: 10.3390/ijms25031557.
4
Survival and Enrichment Analysis of Epithelial-Mesenchymal Transition Genes in Bladder Urothelial Carcinoma.膀胱癌中上皮-间充质转化基因的生存和富集分析。
Genes (Basel). 2023 Sep 30;14(10):1899. doi: 10.3390/genes14101899.
5
CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells.CUDC-101 是一种针对 EGFR 过表达膀胱癌细胞的潜在靶向抑制剂。
Int J Oncol. 2023 Dec;63(6). doi: 10.3892/ijo.2023.5579. Epub 2023 Oct 13.
6
Early diagnosis and prognostic potential of RAC3 in bladder tumor.RAC3 在膀胱癌中的早期诊断和预后潜力。
Int Urol Nephrol. 2024 Feb;56(2):475-482. doi: 10.1007/s11255-023-03781-0. Epub 2023 Sep 20.
7
A global, regional, and national survey on burden and Quality of Care Index (QCI) of bladder cancer: The global burden of disease study 1990-2019.全球、区域和国家膀胱癌负担和护理质量指数（QCI）调查：1990-2019 年全球疾病负担研究。
PLoS One. 2022 Oct 20;17(10):e0275574. doi: 10.1371/journal.pone.0275574. eCollection 2022.
8
Optimized Adaptive Radiotherapy with Individualized Plan Library for Muscle-Invasive Bladder Cancer Using Internal Target Volume Generation.使用内部靶区体积生成技术的个性化计划库优化自适应放疗用于肌肉浸润性膀胱癌
Cancers (Basel). 2022 Sep 26;14(19):4674. doi: 10.3390/cancers14194674.
9
Diabetes Is a Risk Factor for the Prognosis of Patients with Bladder Cancer: A Meta-Analysis.糖尿病是膀胱癌患者预后的一个危险因素：一项荟萃分析。
J Oncol. 2022 Sep 26;2022:1997507. doi: 10.1155/2022/1997507. eCollection 2022.
10
The value of BCL2 and CK20 expression in predicting behavioral patterns of bladder cancer, a cross sectional study.BCL2和CK20表达在预测膀胱癌行为模式中的价值：一项横断面研究
Ann Med Surg (Lond). 2022 Aug 23;81:104372. doi: 10.1016/j.amsu.2022.104372. eCollection 2022 Sep.
本文引用的文献
1
National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013.美国 2004-2013 年根治性膀胱切除术治疗尿路上皮膀胱癌后辅助放疗的国家实践模式和总体生存。
Eur Urol Oncol. 2020 Jun;3(3):343-350. doi: 10.1016/j.euo.2018.11.010. Epub 2018 Dec 19.
2
Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. bladder 保留的三联疗法与根治性膀胱切除术治疗肌层浸润性膀胱癌的疗效比较。
Clin Genitourin Cancer. 2019 Feb;17(1):23-31.e3. doi: 10.1016/j.clgc.2018.09.023. Epub 2018 Oct 4.
3
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.每日两次放疗联合氟尿嘧啶和顺铂或每日一次放疗联合吉西他滨用于肌层浸润性膀胱癌的膀胱保留：NRG/RTOG 0712-A 随机 II 期试验。
J Clin Oncol. 2019 Jan 1;37(1):44-51. doi: 10.1200/JCO.18.00537. Epub 2018 Nov 15.
4
National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging.国家癌症数据库比较肌层浸润性膀胱癌根治性膀胱切除术与放化疗：临床分期与病理分期的应用意义。
Cancer Med. 2018 Nov;7(11):5370-5381. doi: 10.1002/cam4.1684. Epub 2018 Oct 10.
5
Long-term Outcomes and Patterns of Failure Following Trimodality Treatment With Bladder Preservation for Invasive Bladder Cancer.浸润性膀胱癌膀胱保留三联疗法后的长期疗效及失败模式
Urology. 2019 Feb;124:183-190. doi: 10.1016/j.urology.2018.07.058. Epub 2018 Sep 25.
6
Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy.基于免疫组织化学的肌肉浸润性膀胱癌亚型对放化疗反应的影响。
Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1408-1416. doi: 10.1016/j.ijrobp.2018.06.030. Epub 2018 Jun 28.
7
Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.比较根治性膀胱切除术与三联疗法治疗肌层浸润性膀胱癌老年患者的生存结局和成本。
JAMA Surg. 2018 Oct 1;153(10):881-889. doi: 10.1001/jamasurg.2018.1680.
8
Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.根治性膀胱切除术后局部晚期膀胱癌辅助夹心化疗联合放疗与单纯辅助化疗的比较：一项随机 2 期试验。
JAMA Surg. 2018 Jan 17;153(1):e174591. doi: 10.1001/jamasurg.2017.4591.
9
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.一线帕博利珠单抗治疗铂类药物治疗禁忌的局部晚期和不可切除或转移性尿路上皮癌患者（KEYNOTE-052）：一项多中心、单臂、2 期研究。
Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.
10
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.根治性膀胱切除术或放化疗联合保膀胱治疗肌层浸润性膀胱癌老年患者：国际尿路上皮癌研究组织（RISC）回顾性研究。
Acta Oncol. 2018 Apr;57(4):491-497. doi: 10.1080/0284186X.2017.1369565. Epub 2017 Aug 30.
Zotero 插件